Reverse cholesterol transport and hepatic osteodystrophy.
Level V
Where this comes from
- Record sourced from PubMed, PMID 35235770.
- Also identified by DOI 10.1016/j.cmet.2022.02.007 and PMC identifier 11658025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Cell Metabolism, Lu et al. show that chronic liver disease increases the expression and activity of PP2Ac, a phosphatase that downregulates the excretion of lecithin-cholesterol aceyltransferase (LCAT). LCAT, a liver-derived enzyme, protects bone and prevents bone loss, and its lowered levels in progressive liver injury cause hepatic osteodystrophy (HOD) and worsen liver fibrosis. These discoveries open the possibility that recombinant LCAT may be a treatment for both HOD and liver fibrosis.
Medical subject headings
- Cholesterol
- Phosphatidylcholine-Sterol O-Acyltransferase